肾功能不全患者的伊曲康唑药代动力学。
Itraconazole pharmacokinetics in patients with renal dysfunction.
作者信息
Boelaert J, Schurgers M, Matthys E, Daneels R, van Peer A, De Beule K, Woestenborghs R, Heykants J
机构信息
Renal Unit, Algemeen Ziekenhuis St. Jan, Brugge, Belgium.
出版信息
Antimicrob Agents Chemother. 1988 Oct;32(10):1595-7. doi: 10.1128/AAC.32.10.1595.
Abstract
The single-dose pharmacokinetics of 200 mg of oral itraconazole were studied in seven uremic patients, seven patients treated by hemodialysis, and five patients treated by continuous ambulatory peritoneal dialysis. Plasma concentration-versus-time profiles showed wide intersubject variation. This study could not demonstrate any significant effect of renal dysfunction and hemodialysis or continuous ambulatory peritoneal dialysis treatment upon the pharmacokinetics of itraconazole, and firm conclusions concerning dosing in such patients should await confirmation of our data in a larger patient population.
摘要
对7名尿毒症患者、7名接受血液透析治疗的患者和5名接受持续性非卧床腹膜透析治疗的患者，研究了口服200毫克伊曲康唑的单剂量药代动力学。血浆浓度-时间曲线显示个体间差异很大。本研究未能证明肾功能不全、血液透析或持续性非卧床腹膜透析治疗对伊曲康唑药代动力学有任何显著影响，关于此类患者给药的明确结论有待在更大患者群体中对我们的数据进行确认。
相似文献
1
Itraconazole pharmacokinetics in patients with renal dysfunction.肾功能不全患者的伊曲康唑药代动力学。
Antimicrob Agents Chemother. 1988 Oct;32(10):1595-7. doi: 10.1128/AAC.32.10.1595.
2
The pharmacokinetics of oral itraconazole in AIDS patients.艾滋病患者口服伊曲康唑的药代动力学。
J Pharm Pharmacol. 1992 Jul;44(7):618-9. doi: 10.1111/j.2042-7158.1992.tb05478.x.
3
The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects.食物和剂量对健康受试者中伊曲康唑口服全身可用性的影响。
Eur J Clin Pharmacol. 1989;36(4):423-6. doi: 10.1007/BF00558308.
4
Pharmacokinetics of itraconazole following oral administration to normal volunteers.伊曲康唑对正常志愿者口服给药后的药代动力学。
Antimicrob Agents Chemother. 1988 Sep;32(9):1310-3. doi: 10.1128/AAC.32.9.1310.
5
Skin kinetics of azole antifungal drugs.
Curr Top Med Mycol. 1992;4:88-136. doi: 10.1007/978-1-4612-2762-5_4.
6
Itraconazole pharmacokinetics in the female genital tract: plasma and tissue levels in patients undergoing hysterectomy after a single dose of 200 mg itraconazole.
Eur J Obstet Gynecol Reprod Biol. 1986 Oct;23(1-2):85-9. doi: 10.1016/0028-2243(86)90109-7.
7
Pharmacokinetics of oral antifungals and their clinical implications.口服抗真菌药物的药代动力学及其临床意义。
Br J Clin Pract Suppl. 1990 Sep;71:50-6.
8
[Acid-base equilibrium in uremia: effect of continuous ambulatory peritoneal dialysis and hemodialysis].
G Clin Med. 1981 Sep;62(9):624-33.
9
Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers.伊曲康唑胶囊在健康男性志愿者中的食物相互作用及稳态药代动力学
Antimicrob Agents Chemother. 1993 Apr;37(4):778-84. doi: 10.1128/AAC.37.4.778.
10
Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration.单次口服剂量后及重复给药期间皮肤水疱液中伊曲康唑的水平。
J Am Acad Dermatol. 1990 Feb;22(2 Pt 1):211-5. doi: 10.1016/0190-9622(90)70026-e.
引用本文的文献
1
StemPanTox: A fast and wide-target drug assessment system for tailor-made safety evaluations using personalized iPS cells.干细胞毒性检测系统：一种利用个性化诱导多能干细胞进行定制化安全性评估的快速且广靶标的药物评估系统。
iScience. 2022 Jun 6;25(7):104538. doi: 10.1016/j.isci.2022.104538. eCollection 2022 Jul 15.
2
Comparative analysis of the effects of rice and bread meals on bioavailability of itraconazole using NONMEM in healthy volunteers.使用NONMEM对健康志愿者进行大米餐和面包餐对伊曲康唑生物利用度影响的比较分析。
Eur J Clin Pharmacol. 2006 Dec;62(12):1033-9. doi: 10.1007/s00228-006-0200-5. Epub 2006 Oct 20.
3
Role of itraconazole in haematology/oncology.伊曲康唑在血液学/肿瘤学中的作用。
Arch Dis Child. 2003 Mar;88(3):258-60. doi: 10.1136/adc.88.3.258.
4
Pharmacokinetics of antifungal agents in onychomycoses.抗真菌药物在甲癣中的药代动力学。
Clin Pharmacokinet. 2001;40(6):441-72. doi: 10.2165/00003088-200140060-00005.
5
Pharmacology of itraconazole.伊曲康唑的药理学
Drugs. 2001;61 Suppl 1:27-37. doi: 10.2165/00003495-200161001-00003.
6
Optimisation of itraconazole therapy using target drug concentrations.使用目标药物浓度优化伊曲康唑治疗。
Clin Pharmacokinet. 1998 Dec;35(6):461-73. doi: 10.2165/00003088-199835060-00004.
7
Pharmacokinetics of drugs used in critically ill adults.危重症成年患者使用药物的药代动力学
Clin Pharmacokinet. 1998 Jan;34(1):25-56. doi: 10.2165/00003088-199834010-00002.
8
Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections.伊曲康唑。对其药理特性及在浅表真菌感染治疗中的应用的重新评估。
Drugs. 1996 Apr;51(4):585-620. doi: 10.2165/00003495-199651040-00006.
9
Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations.持续肾脏替代治疗患者的药物剂量。药代动力学及治疗方面的考量。
Clin Pharmacokinet. 1993 May;24(5):362-79. doi: 10.2165/00003088-199324050-00002.
10
Pharmacokinetic optimisation of oral antifungal therapy.口服抗真菌治疗的药代动力学优化
Clin Pharmacokinet. 1993 Oct;25(4):329-41. doi: 10.2165/00003088-199325040-00006.
本文引用的文献
1
Determination of itraconazole in plasma and animal tissues by high-performance liquid chromatography.高效液相色谱法测定血浆及动物组织中的伊曲康唑
J Chromatogr. 1987 Jan 23;413:332-7. doi: 10.1016/0378-4347(87)80249-9.
2
Itraconazole: pharmacologic studies in animals and humans.伊曲康唑：在动物和人类中的药理学研究。
Rev Infect Dis. 1987 Jan-Feb;9 Suppl 1:S43-6. doi: 10.1093/clinids/9.supplement_1.s43.
3
Pharmacokinetics of itraconazole following oral administration to normal volunteers.伊曲康唑对正常志愿者口服给药后的药代动力学。
Antimicrob Agents Chemother. 1988 Sep;32(9):1310-3. doi: 10.1128/AAC.32.9.1310.
4
Azole antifungal agents: emphasis on new triazoles.唑类抗真菌药物：重点介绍新型三唑类药物。
Antimicrob Agents Chemother. 1988 Jan;32(1):1-8. doi: 10.1128/AAC.32.1.1.
Zotero 插件